KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Alexandre is Director of Molecular Biology for Selexis. Alexandre joined Selexis in 2007 with a focus on improving the SUREtech Vectors, as well as engineering the SURE CHO-M Cell Line. Currently, he is responsible for the generation of all expression vectors for clients’ projects and the R&D on the Selexis SURE CHO-Mplus™ Libraries and SUREtech Vectors™.
Alexandre’s PhD and first postdoctoral fellowship, which were completed at the University of Lausanne (CH) and the University of Sydney (AUS), consisted of the study of chromosomal rearrangements and the link between replication and division cycles in Bacillus subtilis, respectively. He then worked as a Research Associate in Oncology at CHUV University Hospital (CH) on the CYLD tumor suppressor gene before joining the Laboratory of Molecular Biotechnology at EPFL FSB LBTM (CH), where he discovered a family of mouse genetic sequences that are involved in the epigenetic regulation of genes.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.